ImmunoGen vice president Charles Morris is leaving
Dr. Morris joined ImmunoGen in November 2012.
Prior to joining ImmunoGen, he was the executive vice president and chief medical officer at Allos Therapeutics where he led the company's clinical development functions including clinical operations, regulatory, and pharmacovigilance.
Prior to joining Allos in 2010, Dr. Morris was vice president worldwide clinical research at Cephalon where he contributed significantly to the company achieving its first approved oncology drug, Treanda (bendamustine).
Prior to joining Cephalon in 2007, Dr. Morris was with AstraZeneca Pharmaceuticals (formerly Zeneca Pharmaceuticals), serving most recently as vice president, clinical development projects, oncology.
He held a number of leadership roles during his more than ten years with AstraZeneca, including managing the clinical development of all late-stage pipeline and marketed oncology products.
Dr. Morris holds Degrees of Bachelor of Medicine, Bachelor of Surgery, and Bachelor of Medical Science in Clinical Pharmacology and Therapeutics from the Sheffield University Medical School, UK, and is a member of the Royal College of Physicians of London.